PSA Test Has Cut Metastatic Prostate Cancer at Presentation

This article originally appeared here.
Share this content:
PSA Test Has Cut Metastatic Prostate Cancer at Presentation
PSA Test Has Cut Metastatic Prostate Cancer at Presentation

(HealthDay News) – If incidence rates for the pre-prostate-specific antigen (PSA) testing era (1983 to 1985) were present in the modern US population, 3 times the number of men would have been expected to present with metastatic (M1) prostate cancer (PC) than the actual number observed in 2008, according to a study published online July 30 in Cancer.

Emil Scosyrev, PhD, from the University of Rochester Medical Center in New York, and colleagues estimated the total number of patients who would be expected to present with M1 PC in the modern US population in a given year if the annual incidence rates of M1 PC were the same as the rates before PSA testing. The total number of men who presented in 2008 in the Surveillance, Epidemiology, and End Results 9 registries area was computed, and the number of cases expected to occur in the absence of PSA testing was estimated.

The researchers found that, in 2008, the observed and expected numbers presenting with M1 PC were 739 and 2,277, respectively, with a 3.1 expected-to-observed ratio. Application of this ratio to the total US population in 2008 would have resulted in approximately 25,000 men presenting with M1 PC, compared with the actual observed number of approximately 8,000 men.

"We believe that these estimates must be taken into consideration (bearing in mind the limitations of observational data) when public health policy-level recommendations are made regarding PSA screening," the authors conclude.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs